多瑞醫藥(301075.SZ):湖北多瑞收到注射用頭孢唑肟鈉藥品註冊受理通知書
格隆匯10月10日丨多瑞醫藥(301075.SZ)公佈,近日,西藏多瑞醫藥股份有限公司全資子公司湖北多瑞藥業有限公司(簡稱“湖北多瑞”)收到國家藥品監督管理局下發的注射用頭孢唑肟鈉藥品註冊受理通知書,國家藥品監督管理局根據《中華人民共和國行政許可法》第三十二條的規定,對上述藥品的藥品註冊申請進行了審查,決定予以受理。
截止公吿披露之日,注射用頭孢唑肟鈉有33家廠商取得藥品註冊批件,但均未通過一致性評價。根據米內網中國城市公立醫院化學藥終端競爭格局顯示,2022年頭孢類銷售額約為410.07億元,其中注射用頭孢唑肟鈉約為37.74億元。品牌排名前三分別為:西南藥業、國藥致君(深圳)製藥、海口製藥,市場份額分別是46.18%、11.37%、11.34%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.